Quick Facts

Therapeutic Domain	Main Uses
Respiratory System	Treatment of symptoms related to bronchopulmonary diseases, such as cough and expectoration.
Respiratory System	Adjunctive treatment for inflammatory diseases of the respiratory tract.

---

Pneumorel, containing the active substance fenspiride, was historically indicated for the management of symptoms associated with various bronchopulmonary conditions. The main therapeutic use was focused on treating symptoms such as cough and expectoration (phlegm/sputum production) linked to respiratory tract and ENT (ear, nose, and throat) inflammatory diseases, including chronic bronchitis and tracheobronchitis. The mechanism of action includes antibronchoconstrictive and anti-inflammatory properties, aiming to alleviate these respiratory discomforts.

Fenspiride was also utilized as a component in the complex therapy for conditions like chronic obstructive pulmonary disease (COPD) and asthma to help manage inflammation and improve clinical signs. The use of fenspiride provided an early clinical benefit in improving lung auscultation findings and a composite clinical score in patients with acute exacerbations of chronic bronchitis. The therapeutic aim was symptomatic relief and mitigation of inflammation in the airways.

Note: Medicinal products containing fenspiride, including Pneumorel, were revoked and withdrawn from the market due to the risk of cardiac rhythm problems.

---

The eligibility for Pneumorel (Fenspiride) is fundamentally defined by the regulatory status of the medicine, which has been subject to a formal withdrawal of marketing authorization in the European Union and other regions due to serious safety concerns.

Eligibility Scope

Eligibility Status	Official Regulatory Stance
Current Eligibility	ALL POPULATIONS are considered ineligible in regions where the authorization is revoked (e.g., EMA jurisdictions).
Absolute Contraindication	Patients with known Hypersensitivity to Fenspiride or excipients.
Age Restriction	Children below the age of 2 years are formally contraindicated.
Physiological Status	Use in pregnant and breastfeeding women is officially not recommended (based on former labeling).

Eligibility Classifications

The most severe classification is the absolute prohibition on marketing and use, mandated by the European Medicines Agency (EMA) due to the confirmed risk of QT interval prolongation and potential for Torsades de Pointes, which are serious heart rhythm problems.

Connection to the overall eligibility profile: The regulatory profile prohibits the use of Pneumorel for all intended patient groups because health authorities determined that the risk of sudden, serious cardiac problems outweighs the benefits, establishing an absolute non-eligibility status that overrides all previous age or condition-based rules.

Interactions with other medicines and products

Official regulatory documents define the product's interaction structure primarily through constraints related to the active substance, Fenspiride hydrochloride, and its potential to disrupt cardiac electrophysiology. This potential mandates the exclusion of agents that share this pharmacodynamic effect.

Interaction Classification and Constraints

The most severe interaction constraint involves medicines that prolong the heart's QT interval. Co-administration with any medicinal product known to cause QT interval prolongation is officially prohibited due to the confirmed additive risk of serious ventricular arrhythmia, such as Torsades de Pointes. This restriction forms the highest-level constraint in the regulatory profile.

Secondary constraints exist due to Fenspiride's established properties. Concomitant use with Central Nervous System (CNS) depressants carries a documented risk of potentiating sedative effects. Likewise, alcohol consumption is restricted for the same reason of exacerbating sedation and other central nervous system effects.

Official warnings also address the potential for pharmacokinetic interactions. Substances that modify the activity of drug-metabolizing Cytochrome P450 (CYP) enzymes (e.g., inhibitors or inducers) may alter the systemic exposure of Fenspiride. The risk of cardiac arrhythmia is further heightened by the presence of predisposing factors, including underlying cardiac conditions or electrolyte imbalances.

How Pneumorel Works: Mechanism of Action

The mechanism of Fenspiride hydrochloride involves its combined capacity to modulate specific receptors and inhibit intracellular enzymes, leading to the regulation of inflammatory and constrictive physiological responses in the airways.

---

Modulation of Acute Signaling via Dual Receptor Antagonism

This core mechanism involves the competitive blockade of H1 Histamine Receptors and alpha1 Adrenergic Receptors. By preventing the binding of histamine and norepinephrine, Fenspiride immediately influences signaling that drives increased microvascular permeability and bronchial smooth muscle tone. This action contributes to decreased vascular leakage and smooth muscle tension in the respiratory tract.

---

Modulation of the Inflammatory Cascade through PDE Inhibition

Fenspiride exerts its anti-inflammatory actions primarily through the inhibition of Phosphodiesterase ( PDE) isoforms, which leads to an increase in intracellular cAMP. This rise in cAMP stabilizes immune cells and suppresses the release and synthesis of pro-inflammatory mediators like cytokines and eicosanoids. This thereby influences the magnitude of the inflammatory cascade and inhibits mucus hypersecretion at the cellular level.

---

Modulation of Neurogenic Afferent Signaling

The molecule engages a mechanism that interferes with the neural component of airway pathology by reducing the release of neuropeptides, such as Tachykinins, from sensory nerve endings ( C-fibers). This action influences the regulation of afferent nerve activity and reflex-mediated exudation, which shapes the resulting physiological modulations of local nerve signaling.

The administration guidelines for the active substance Fenspiride (Pneumorel) focused on the method and schedule of intake. The medicine was indicated for oral administration. It was made available in conventional 80 mg film-coated tablets and various liquid preparations, including a syrup or oral solution.

The total daily dose was required to be administered in divided portions, typically two or three times daily. For adults, the dosage range was generally 160 mg to 240 mg per day when using the tablet form. A primary procedural instruction stipulated that Fenspiride must be taken directly before meals.

Specific rules governed administration for different populations. Use was contraindicated in children below 2 years of age. For pediatric patients over two years, the total daily amount was calculated based on body weight, using a guideline of 4 mg per 1 kg body weight per day.

Proper use of the liquid formulations required utilizing the dedicated oral measuring device (spoon or syringe) included with the product to ensure dose accuracy. Furthermore, a patient should not double a dose to compensate for a missed scheduled intake. The duration of use was designated as being determined by the prescribing physician, consistent with a protocol for symptomatic treatment.

Evidence for Inflammatory Bronchopulmonary Diseases

Fenspiride was evaluated in research exploring conditions characterized by fluctuating or episodic manifestations, including chronic bronchitis, acute bronchitis, and episodes where symptoms become more noticeable in COPD. Research primarily used Randomized Controlled Trials (RCTs), often conducted in multiple centers, which included placebo as a comparator group. These studies involved adults, monitoring outcomes related to physical discomfort such as cough severity and dyspnea, alongside objective markers like certain lung function tests (such as FEV1) and documented shifts in inflammatory markers.

Findings describe patterns observed in the studies related to how symptoms evolved, and research provides insight into short-term changes. However, evidence often derived from scenarios where fenspiride was evaluated alongside concurrent standard medications. Consequently, comparative evidence is lacking to fully characterize the observed patterns when fenspiride was not administered with a concurrent treatment.

Evidence for Inflammatory ENT (Ear, Nose, and Throat) Conditions

Fenspiride was also evaluated in RCTs for conditions like chronic sinusitis. These studies monitored patient-reported outcomes describing perceived discomfort and objective radiological changes, such as those measured by Computed Tomography scans. The quantity of published evidence for ENT conditions is modest, and research often assessed the compound as part of a complex treatment regimen.

Long-Term Research and Durability of Response

Clinical trials included observation periods ranging from short-term to medium-term, sometimes lasting up to six months. While research provides context for these periods, long-term effects are not fully established. There is limited information regarding the durability of any observed patterns beyond the six-month study period.

Evidence in Specific Patient Groups and Remaining Uncertainty

Research has concentrated on adult study populations across the relevant indications. Data for certain groups remain insufficient; for instance, evidence is limited regarding outcomes in pediatric populations, pregnant populations, or older adults with comorbidities. Additionally, evidence quality varies across studies, and many include modest sample sizes, meaning the ability to generalize findings is limited.

Common questions about Pneumorel (FAQ)

---

Q: How is the action of Pneumorel described in official medical sources?

According to official product information and medical classification sources, the active ingredient in Pneumorel, Fenspiride, is fundamentally classified as an agent that possesses both anti-inflammatory and bronchodilator properties. It is also noted as an H1-receptor antagonist and an alpha-adrenolytic agent, which relates to its effects on reducing swelling and relaxing the airways.

Q: Is Pneumorel a type of antibiotic?

No, the active ingredient in Pneumorel is not classified as an antibiotic. Official sources classify the medicine pharmacologically as a non-steroidal compound with anti-inflammatory and bronchodilator properties, used for symptomatic relief of inflammatory respiratory conditions.

Q: Does Pneumorel need to be taken with food?

Administration instructions explicitly stipulated that the medicine was to be taken directly before meals. This guidance was a core part of the official administration protocol defined by regulatory authorities.

Q: How quickly does Pneumorel start working?

Regulatory studies focused on observing symptomatic changes over short-to-medium-term periods rather than defining a specific time of onset (e.g., in minutes or hours). Pharmacokinetic information indicates that the elimination half-life of the active ingredient is approximately 14 to 16 hours, which provides context for the systemic exposure of the substance.

Q: What is the typical time frame for noticing the intended effect of Pneumorel?

Clinical research evidence, which monitored symptom outcomes like cough severity, provides insight into patterns observed over short-term periods, such as within 7 to 14 days of use. However, a standardized time frame for when a patient might typically notice an effect is not explicitly defined in the regulatory documents.

Q: Can I take Pneumorel if I have a cough?

Official documentation indicates the medicine was authorized for the symptomatic treatment of cough and expectoration associated with inflammatory diseases of the bronchi and lungs. The medicine was indicated for the relief of non-serious cough symptoms.

Q: Can Pneumorel cause stomach upset?

Official product information documented Gastrointestinal disorders among the known adverse reactions prior to the medicine's withdrawal. These effects included specific mentions of nausea, vomiting, and stomach pain.

Q: Is it common to feel sleepy after taking Pneumorel?

Prior product information documented side effects under 'Nervous system disorders,' which included drowsiness or dizziness. Although the frequency of these effects was not always clearly classified, warnings were in place regarding the potential to impair the ability to drive or use machinery due to central nervous system effects.

Q: Can Pneumorel cause a skin rash?

Prior to the market withdrawal, official product labels for the active ingredient sometimes documented cases of skin reactions, including rash, as a potential adverse effect.

Q: Can Pneumorel be taken with vitamins or supplements?

Official regulatory information does not specifically address vitamins or general supplements. However, official warnings do exist for substances that can modify Cytochrome P450 (CYP) enzymes, as these could potentially alter the way the active ingredient is processed by the body.

Q: What is the maximum duration of use described for Pneumorel?

Official administration guidance stated that the duration of use was determined by the prescribing physician, consistent with the protocol for symptomatic treatment. Clinical trials included observation periods sometimes lasting up to six months.

Q: Do studies suggest Pneumorel can prevent respiratory infections?

The medicine was indicated for symptomatic relief. Regulatory documents specify the medicine should not delay the initiation of antibiotics if necessary, indicating its role was supportive for symptoms, not preventative of infections.

Q: How is Pneumorel eliminated from the body?

Pharmacokinetic data from official sources indicate that the active ingredient is primarily eliminated from the body through the urine, accounting for approximately 90% of the excretion. The remaining amount is eliminated in the feces.

Q: What information is available about discontinuing Pneumorel treatment?

Due to the serious safety risks identified, regulatory bodies officially mandated the immediate cessation of its use and instructed patients to return any unused stock to a pharmacy or designated collection point for appropriate disposal.

Official Storage and Disposal Requirements

The regulatory status of Pneumorel (Fenspiride) means that official instructions cover both historical storage constraints and the mandatory post-recall disposal directives issued by health authorities.

Historically, official labeling required the medicine to be stored in its original packaging at a temperature below 25 C and protected from light and humidity. The mandatory safety constraint requires that the medicine always be stored out of the sight and reach of children.

Due to the market withdrawal based on safety concerns, the official disposal rule supersedes standard methods. All remaining stock of Pneumorel must be returned to a pharmacy or designated collection point for proper handling as pharmaceutical waste, prohibiting disposal in household trash or via wastewater.